Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.259 - Healthcare interoperability: the promises and pitfalls relating to penicillin allergy delabelling
D1.250 - Beyond the Label: A Multidisciplinary Effort to De-label Penicillin Allergy
D1.251 - Documentation of drug allergy in the Electronic Health Record (EHR) at a Tertiary paediatric allergy service in the UK
D1.252 - A model based economic evaluation to assess impact of Penicillin Allergy in COPD patients
D1.253 - Comparison of Immune-Related Adverse Events in Patients Treated with Atezolizumab and Durvalumab: A Critical Concern for Clinical Management
D1.254 - Assessing the Accuracy of Penicillin Allergy Labels in Paediatric Care: Focusing on Educational Gaps in Both Families and Healthcare Workers
D1.255 - Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q): A Cross-Cultural Adaptation and Reliability Study
D1.256 - Development of multiple drug hypersensitivity after DRESS syndrome induced by piperacillin/tazobactam
D1.257 - Extensive allergological workup in the management of immediate adverse drug reactions to chemotherapy- a single centre experience
D1.258 - Comparison of the Negative Predictive Values of One-Day and Five-Day Drug Provocation Tests in Late-Mild and Cutaneous Beta-Lactam Allergies in Children
D1.260 - Hypersensitivity to Iodinated Contrast Media: Diagnostic Evaluation and Re-exposure Outcomes
D1.248 - Perioperative hypersensitivity reaction (POH) with tranexamic acid: study of 2 cases
D1.249 - Improving inpatient antimicrobial stewardship through single dose oral amoxicillin challenge among penicillin allergic veterans
D3.178 - Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies
D3.179 - Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience
D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme
D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden
D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy
D3.184 - Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study
D3.185 - The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download